Discovering the Biological Significance and Therapeutic Potential of miR-29b-3p in Triple-Negative Breast Cancer

被引:2
|
作者
Jurj, Ancuta [1 ]
Zanoaga, Oana [1 ]
Raduly, Lajos [1 ]
Morhan, Vlad [2 ]
Papi, Zsofia [3 ]
Ciocan, Cristina [1 ]
Pop, Laura-Ancuta [1 ]
Berindan-Neagoe, Ioana [1 ]
Braicu, Cornelia [1 ]
机构
[1] Iuliu Hatieganu Univ Med & Pharm, Res Ctr Funct Genom, Biomed & Translat Med, Cluj Napoca 400347, Romania
[2] Iuliu Hatieganu Univ Med & Pharm, Fac Med, Cluj Napoca 400347, Romania
[3] Univ Szeged, Fac Med, H-6720 Szeged, Hungary
关键词
miR-29b-3p inhibitor; triple-negative breast cancer; miRNA; drug resistance; EPITHELIAL-MESENCHYMAL TRANSITION; CELLS; EXPRESSION; GROWTH;
D O I
10.3390/ijms24055048
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The lack of estrogen or progesterone receptors and absence of HER2 amplification/overexpression in triple-negative breast cancer (TNBC) restricts therapeutic options used in clinical management. MicroRNAs (miRNAs) are small, non-coding transcripts which affect important cellular mechanisms by regulating gene expression at the post-transcriptional level. Among this class, attention was focused on miR-29b-3p with a high profile in TNBC and correlated with the overall survival rates, as TCGA data revealed. This study aims to investigate the implication of the miR-29b-3p inhibitor in TNBC cell lines by identifying a potential therapeutic transcript, improving the clinical outcomes of this disease. The experiments were performed on two TNBC cell lines (MDA-MB-231 and BT549) as in vitro models. An established dose of 50 nM was used for all functional assays performed on the miR-29b-3p inhibitor. A decreased level of miR-29b-3p determined a significant reduction in cell proliferation and colony-forming capacity. At the same time, the changes occurring at the molecular and cellular levels were highlighted. We observed that, when inhibiting the expression level of miR-29b-3p, processes such as apoptosis and autophagy were activated. Further, microarray data revealed that the miRNA expression pattern was altered after miR-29b-3p inhibition, pointing out 8 overexpressed and 11 downregulated miRNAs specific for BT549 cells and 33 upregulated and 10 downregulated miRNAs that were specific for MDA-MB-231 cells. As a common signature for both cell lines, three transcripts were observed, two downregulated, miR-29b-3p and miR-29a, and one upregulated, miR-1229-5p. According to DIANA miRPath, the main predicted targets are related to ECM (extracellular matrix) receptor interaction and TP53 signaling. An additional validation step through qRT-PCR was performed, which showed an upregulation of MCL1 and TGFB1. By inhibiting the expression level of miR-29b-3p, it was shown that complex regulatory pathways targeted this transcript in TNBC cells.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Significance of the vimentin expression in triple-negative breast cancer
    Yamashita, Nami
    Tokunaga, Eriko
    Kitao, Hiroyuki
    Tanaka, Kimihiro
    Taketani, Kenji
    Saeki, Hiroshi
    Aishima, Shinichi
    Oki, Eiji
    Morita, Masaru
    Maehara, Yoshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [32] Prognostic significance of triple-negative phenotype in breast cancer
    Choi, M. Y.
    Lee, K. E.
    Chang, H. J.
    Sung, S. H.
    Moon, B. I.
    Choi, H. Y.
    Suh, H. S.
    Nam, E. M.
    Mun, Y. C.
    Seong, C. M.
    Lee, S. N.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Prognostic significance of triple-negative phenotype in breast cancer
    Lee, K. E.
    Choi, M. Y.
    Chang, H. J.
    Sung, S. H.
    Moon, B. I.
    Choi, H. Y.
    Nam, E. M.
    Mun, Y. C.
    Seong, C. M.
    Lee, S. N.
    EJC SUPPLEMENTS, 2008, 6 (07): : 188 - 188
  • [34] Significance of Histomorphology of Early Triple-Negative Breast Cancer
    Rubovszky, Gabor
    Horvath, Zsolt
    Toth, Erika
    Lang, Istvan
    Kasler, Miklos
    PATHOLOGY & ONCOLOGY RESEARCH, 2012, 18 (04) : 823 - 831
  • [35] CXCL16 as a potential therapeutic target of triple-negative breast cancer
    Cho, Sun Wook
    Jang, Mi Gyeong
    Sun, Hyun Jin
    Lee, Han Sai
    Song, Young Shin
    Kim, Seong Keun
    CANCER RESEARCH, 2022, 82 (04)
  • [36] LRP5: a Potential Therapeutic Target in Triple-negative Breast Cancer
    Maubant, S.
    Maire, V.
    Tesson, B.
    Gentien, D.
    Marty-Prouvose, B.
    Cruzalegui, F.
    Depil, S.
    Tucker, G. C.
    Roman-Roman, S.
    Dubois, T.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 161 - 162
  • [37] PARP1 in triple-negative breast cancer: Expression and therapeutic potential
    Cotter, M. B.
    Pierce, A.
    McGowan, P. M.
    Madden, S. F.
    Flanagan, L.
    Quinn, C.
    Evoy, D.
    Crown, J.
    McDermott, E.
    Duffy, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [38] LRP5: a potential therapeutic target in triple-negative breast cancer
    Maubant, Sylvie
    Maire, Virginie
    Tesson, Bruno
    Gentien, David
    Marty-Prouvost, Berengere
    Cruzalegui, Francisco
    Depil, Stephane
    Tucker, Gordon C.
    Roman-Roman, Sergio
    Dubois, Thierry
    CANCER RESEARCH, 2013, 73 (08)
  • [39] Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
    Jezequel, Pascal
    Kerdraon, Olivier
    Hondermarck, Hubert
    Guerin-Charbonnel, Catherine
    Lasla, Hamza
    Gouraud, Wilfried
    Canon, Jean-Luc
    Gombos, Andrea
    Dalenc, Florence
    Delaloge, Suzette
    Lemonnier, Jerome
    Loussouarn, Delphine
    Verriele, Veronique
    Campone, Mario
    BREAST CANCER RESEARCH, 2019, 21 (1):
  • [40] Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications
    Pascal Jézéquel
    Olivier Kerdraon
    Hubert Hondermarck
    Catherine Guérin-Charbonnel
    Hamza Lasla
    Wilfried Gouraud
    Jean-Luc Canon
    Andrea Gombos
    Florence Dalenc
    Suzette Delaloge
    Jérôme Lemonnier
    Delphine Loussouarn
    Véronique Verrièle
    Mario Campone
    Breast Cancer Research, 21